好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Bilateral Parsonage-Turner Syndrome Due to Cytomegalovirus in Two Immunocompetent Men
Neuromuscular and Clinical Neurophysiology (EMG)
P10 - Poster Session 10 (5:00 PM-6:00 PM)
11-006
NA

Parsonage-Turner Syndrome (PTS), also known as neuralgic amyotrophy or brachial neuritis is thought to be an inflammatory process affecting the peripheral nerves. It presents with acute, asymmetric upper limb pain, with multifocal sensorimotor neuropathies. The incidence is ~3 per 100,000. Aetiologies include toxic, autoimmune, post viral and post radiation effects.

Cytomegalovirus (CMV)  can cause severe systemic conditions in immunocompromised people. It is typically asymptomatic in healthy individuals but has been rarely associated with PTS

NA
Two  immunocompetent men aged 23 and 18 years with no medical history presented with a sudden onset of severe shoulder pain, which progressed bilaterally, resulting in  patchy  sensorimotor deficits. Both men experienced transient abnormalities in Liver  Enzymes, reflecting a systemic response to CMV. Each received opiate analgesia and IVIG, with little clinical improvement. Once serum CMV IgM was confirmed, each received a course of Valgangciclovir. MR Imaging with contrast reported abnormal STIR high signal in the left brachial plexus, suggesting an inflammatory process in the first patient. MR Imaging (non-contrast) performed at day 12 of symptoms was normal in the second man. The first patient partially recovered over a five month period with residual deficits in his left finger flexion (4-/5) and extension (3/5). The second case is embarking on rehabilitation presently

We present two cases of young, healthy men who presented  similarly and were found to be CMV positive. Conventional treatment approaches includes immunoglobulins or steroids but these are usually ineffective.  Early identification of CMV prompted Valgangcyclovir use. The recognition of PTS relies on high suspicion from the clinical history- imaging and NCS are frequently used but have low sensitivity. These cases highlight the need for a comprehensive work-up to identify possible triggers and augment treatment accordingly. Prognosis is favourable with up to 90% of patients having a good outcome at 2 years. 

Authors/Disclosures
Sarah L. Mangan, MBBS
PRESENTER
Dr. Mangan has nothing to disclose.
Shameer Rafee, MBBS Dr. Rafee has nothing to disclose.
Grainne Mulkerrin, MB BCh BAO MSc (Miramar) Dr. Mulkerrin has nothing to disclose.
Christopher McGuigan, MD (Department of Neurology, St. Vincent's University Hospital) An immediate family member of Prof. McGuigan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Prof. McGuigan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Prof. McGuigan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. The institution of Prof. McGuigan has received research support from Novartis.
Justin Kinsella, MD (St.Vincent's University Hospital) Dr. Kinsella has nothing to disclose.